Skip to search formSkip to main contentSkip to account menu

CT-2103

Known as: CT2103 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

paclitaxel poliglumex

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
A Cell-Based Pharmacokinetics Assay for Evaluating Tubulin-Binding Drugs
Increasing evidence reveals that traditional pharmacokinetics parameters based on plasma drug concentrations are insufficient to… 
2011
2011
Phase II trial of paclitaxel poliglumex (CT-2103) in pre- and post-menopausal women on hormonal replacement therapy (HRT) with non-small cell lung cancer (NSCLC).
e18047 Background: Relationship of estrogen use, smoking, and NSCLC has been reported in several studies. Capthesin B is… 
2006
2006
Phase II Study of CT-2103 in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Review
2004
Review
2004
CT-2103: a novel macromolecular taxane with potential advantages compared with conventional taxanes.
CT-2103 (Xyotax) is a polymer-drug conjugate designed to improve upon the therapeutic index and tolerability of conventional… 
Review
2004
Review
2004
CT-2103: emerging utility and therapy for solid tumours
CT-2103 (XYOTAX™, Cell Therapeutics, Inc.) is a conjugate of paclitaxel to a polyglutamate polymer. Its macromolecular nature… 
Review
2004
Review
2004
Improving the toxicity profile of chemotherapy for advanced ovarian cancer: a potential role for CT-2103.
Significant progress has been made in the management of advanced ovarian cancer. Response rates to platinum-based chemotherapy… 
2004
2004
Emerging advances in the management of lung cancer.
Surgery has been the accepted standard of care for early-stage non–small-cell lung cancer (NSCLC). However, the great majority of… 
2003
2003
O-140 Phase 2 study of first line chemotherapy using CT-2103 (XYOTAX™) in patients with non-small-cell lung cancer who are ≥ 70 years of age or performance status (PS) = 2
2002
2002
Metabolism of poly-l-glutamic acid (PG) paclitaxel (CT-2103); characterization of metabolites generated through proteolysis by lysosomal cathepsin B
2001
2001
Pharmacological study of CT-2103 (XyotaxTM), a poly(L-glutamic acid)-paclitaxel conjugate administered every 3 weeks or every 2 weeks in a phase I study
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)